Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to report its financial and operating results for the third quarter ended September 30, 2025. The company issued a press release on October 28, 2025, detailing these results, which is being furnished as an exhibit to this filing. Investors should refer to the press release (Exhibit 99.1) for specific financial figures and operational updates, as it contains the core information regarding the company's performance during the period. The filing itself primarily serves as a notification and mechanism to incorporate the press release into the SEC's public record. While the 8-K does not contain the detailed financial tables or management commentary directly, the attached press release is the key document for understanding Regeneron's recent performance and outlook. Investors are advised to review this press release thoroughly for a comprehensive understanding of the reported results.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. announced its third quarter 2025 financial and operating results on October 28, 2025.
- 2The detailed results are provided in a press release furnished as Exhibit 99.1 to the Form 8-K.
- 3The filing pertains to the period ending September 30, 2025.
- 4Investors need to access the press release (Exhibit 99.1) for specific financial and operational data.
- 5The Form 8-K serves as a notification and incorporation mechanism for the press release content.